Cumberland Pharmaceuticals Inc.
CPIX
$2.13
-$0.06-2.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -7.48% | 28.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.48% | 12.24% | |||
| Cost of Revenue | 41.08% | -27.87% | |||
| Gross Profit | -14.20% | 21.61% | |||
| SG&A Expenses | 6.03% | -11.31% | |||
| Depreciation & Amortization | 0.12% | -31.12% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.17% | -15.12% | |||
| Operating Income | -157.86% | 170.14% | |||
| Income Before Tax | -158.18% | 164.02% | |||
| Income Tax Expenses | 0.00% | 110.00% | |||
| Earnings from Continuing Operations | -158.90% | 165.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -161.80% | 504.55% | |||
| Net Income | -158.92% | 166.03% | |||
| EBIT | -157.86% | 170.14% | |||
| EBITDA | -87.67% | 772.31% | |||
| EPS Basic | -158.86% | 161.70% | |||
| Normalized Basic EPS | -158.11% | 160.36% | |||
| EPS Diluted | -162.50% | 157.06% | |||
| Normalized Diluted EPS | -159.34% | 159.11% | |||
| Average Basic Shares Outstanding | 0.12% | 6.95% | |||
| Average Diluted Shares Outstanding | -1.96% | 9.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||